← Axalta Coating Systems overview

Axalta Coating Systems vs International Flavors & Fragrances: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Axalta Coating Systems Ltd (AXTA)

Q3 2026
▲3

Axalta's Akzo merger clears EU hurdle as earnings stay strong

  • EU regulators set to clear Akzo deal with divestments AkzoNobel will sell overlapping vehicle-refinish businesses to satisfy EU regulators, who are expected to approve the $25 billion all-stock merger; the powder-coating concern was dropped. Removing this regulatory block makes the deal far more likely to close, supporting AXTA's price.

    This is the biggest new force: the merger's key regulatory hurdle is being cleared.

  • Q2 beat: record EBITDA, revenue and EPS above estimates Axalta posted record quarterly adjusted EBITDA of $305 million at a 22.7% margin, revenue up 3.1% to $1.35 billion and EPS of $0.72, both beating estimates, with Refinish and Mobility growing. Strong results and maintained guidance support the stock.

    The quarter's results are the core fundamental driver behind the shares.

  • Governance sweeteners and Akzo's own profit growth After shareholder talks, the combined company will hold annual director elections and lower a key approval threshold to two-thirds. AkzoNobel also reported higher Q2 profit and said the merger is on track, with a shareholder vote set for August 5.

    These steps reduce deal risk and show the partner is financially healthy.

  • Fairness probe and valuation debate temper the good news A law firm is investigating whether Axalta's shareholders get a fair deal, which could pressure terms. Meanwhile one valuation model calls the stock about 30% overvalued near $35.81, while a cash-flow model sees it far higher, so views on worth are split.

    This is the real counterweight: legal risk to the deal and disagreement over what the shares are worth.

August 2026
▲3

Axalta's Akzo merger clears EU hurdle as earnings stay strong

  • EU regulators set to clear Akzo deal with divestments AkzoNobel will sell overlapping vehicle-refinish businesses to satisfy EU regulators, who are expected to approve the $25 billion all-stock merger; the powder-coating concern was dropped. Removing this regulatory block makes the deal far more likely to close, supporting AXTA's price.

    This is the biggest new force: the merger's key regulatory hurdle is being cleared.

  • Q2 beat: record EBITDA, revenue and EPS above estimates Axalta posted record quarterly adjusted EBITDA of $305 million at a 22.7% margin, revenue up 3.1% to $1.35 billion and EPS of $0.72, both beating estimates, with Refinish and Mobility growing. Strong results and maintained guidance support the stock.

    The quarter's results are the core fundamental driver behind the shares.

  • Governance sweeteners and Akzo's own profit growth After shareholder talks, the combined company will hold annual director elections and lower a key approval threshold to two-thirds. AkzoNobel also reported higher Q2 profit and said the merger is on track, with a shareholder vote set for August 5.

    These steps reduce deal risk and show the partner is financially healthy.

  • Fairness probe and valuation debate temper the good news A law firm is investigating whether Axalta's shareholders get a fair deal, which could pressure terms. Meanwhile one valuation model calls the stock about 30% overvalued near $35.81, while a cash-flow model sees it far higher, so views on worth are split.

    This is the real counterweight: legal risk to the deal and disagreement over what the shares are worth.

Latest
▲3

Axalta's Akzo merger clears EU hurdle as earnings stay strong

  • EU regulators set to clear Akzo deal with divestments AkzoNobel will sell overlapping vehicle-refinish businesses to satisfy EU regulators, who are expected to approve the $25 billion all-stock merger; the powder-coating concern was dropped. Removing this regulatory block makes the deal far more likely to close, supporting AXTA's price.

    This is the biggest new force: the merger's key regulatory hurdle is being cleared.

  • Q2 beat: record EBITDA, revenue and EPS above estimates Axalta posted record quarterly adjusted EBITDA of $305 million at a 22.7% margin, revenue up 3.1% to $1.35 billion and EPS of $0.72, both beating estimates, with Refinish and Mobility growing. Strong results and maintained guidance support the stock.

    The quarter's results are the core fundamental driver behind the shares.

  • Governance sweeteners and Akzo's own profit growth After shareholder talks, the combined company will hold annual director elections and lower a key approval threshold to two-thirds. AkzoNobel also reported higher Q2 profit and said the merger is on track, with a shareholder vote set for August 5.

    These steps reduce deal risk and show the partner is financially healthy.

  • Fairness probe and valuation debate temper the good news A law firm is investigating whether Axalta's shareholders get a fair deal, which could pressure terms. Meanwhile one valuation model calls the stock about 30% overvalued near $35.81, while a cash-flow model sees it far higher, so views on worth are split.

    This is the real counterweight: legal risk to the deal and disagreement over what the shares are worth.

International Flavors & Fragrances Inc (IFF)

Q3 2026
▲3▼1

IFF's big portfolio overhaul and buyback drive the story

  • IFF sells Food Ingredients for $3.8B and launches $2.5B buyback IFF agreed to sell its Food Ingredients unit to CVC for about $3.8 billion and announced a $2.5 billion share buyback, including a $500 million accelerated repurchase. This shrinks the company but sharpens focus on higher-margin Taste, Scent, and Health & Biosciences, and returning cash supports the stock.

    This is the biggest strategic event of the period, reshaping IFF's business and capital returns.

  • Q2 results miss and guidance cut on stranded costs IFF's Q2 revenue fell 29% to $1.95 billion and missed estimates badly, while full-year guidance was cut to $7.5 billion. Management blamed temporary stranded costs from the divestiture, but the miss and lower outlook weigh on investor confidence.

    The earnings miss and guidance cut are the main negative counterweight to the positive portfolio moves.

  • New product launches in scent and animal nutrition IFF launched SENSORA pro-fragrance technology, Omni-Bos PHY enzyme for dairy cattle, and AQUASCENT water-based fragrance carrier. These innovations target higher-margin growth areas and support the company's focus on R&D-led differentiation.

    Product launches show IFF's innovation pipeline and support future revenue growth.

  • Analysts and value funds see IFF as undervalued Morgan Stanley and Argus raised price targets, and Heartland Mid Cap Value Fund called IFF a deep-value opportunity trading at a discount to Givaudan. The new buyback and portfolio streamlining are seen as catalysts to close the valuation gap.

    This reflects external validation of IFF's turnaround story and potential upside.

August 2026
▲3▼1

IFF's big portfolio overhaul and buyback drive the story

  • IFF sells Food Ingredients for $3.8B and launches $2.5B buyback IFF agreed to sell its Food Ingredients unit to CVC for about $3.8 billion and announced a $2.5 billion share buyback, including a $500 million accelerated repurchase. This shrinks the company but sharpens focus on higher-margin Taste, Scent, and Health & Biosciences, and returning cash supports the stock.

    This is the biggest strategic event of the period, reshaping IFF's business and capital returns.

  • Q2 results miss and guidance cut on stranded costs IFF's Q2 revenue fell 29% to $1.95 billion and missed estimates badly, while full-year guidance was cut to $7.5 billion. Management blamed temporary stranded costs from the divestiture, but the miss and lower outlook weigh on investor confidence.

    The earnings miss and guidance cut are the main negative counterweight to the positive portfolio moves.

  • New product launches in scent and animal nutrition IFF launched SENSORA pro-fragrance technology, Omni-Bos PHY enzyme for dairy cattle, and AQUASCENT water-based fragrance carrier. These innovations target higher-margin growth areas and support the company's focus on R&D-led differentiation.

    Product launches show IFF's innovation pipeline and support future revenue growth.

  • Analysts and value funds see IFF as undervalued Morgan Stanley and Argus raised price targets, and Heartland Mid Cap Value Fund called IFF a deep-value opportunity trading at a discount to Givaudan. The new buyback and portfolio streamlining are seen as catalysts to close the valuation gap.

    This reflects external validation of IFF's turnaround story and potential upside.

Latest
▲3▼1

IFF's big portfolio overhaul and buyback drive the story

  • IFF sells Food Ingredients for $3.8B and launches $2.5B buyback IFF agreed to sell its Food Ingredients unit to CVC for about $3.8 billion and announced a $2.5 billion share buyback, including a $500 million accelerated repurchase. This shrinks the company but sharpens focus on higher-margin Taste, Scent, and Health & Biosciences, and returning cash supports the stock.

    This is the biggest strategic event of the period, reshaping IFF's business and capital returns.

  • Q2 results miss and guidance cut on stranded costs IFF's Q2 revenue fell 29% to $1.95 billion and missed estimates badly, while full-year guidance was cut to $7.5 billion. Management blamed temporary stranded costs from the divestiture, but the miss and lower outlook weigh on investor confidence.

    The earnings miss and guidance cut are the main negative counterweight to the positive portfolio moves.

  • New product launches in scent and animal nutrition IFF launched SENSORA pro-fragrance technology, Omni-Bos PHY enzyme for dairy cattle, and AQUASCENT water-based fragrance carrier. These innovations target higher-margin growth areas and support the company's focus on R&D-led differentiation.

    Product launches show IFF's innovation pipeline and support future revenue growth.

  • Analysts and value funds see IFF as undervalued Morgan Stanley and Argus raised price targets, and Heartland Mid Cap Value Fund called IFF a deep-value opportunity trading at a discount to Givaudan. The new buyback and portfolio streamlining are seen as catalysts to close the valuation gap.

    This reflects external validation of IFF's turnaround story and potential upside.